Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q92871

UPID:
PMM1_HUMAN

ALTERNATIVE NAMES:
PMMH-22

ALTERNATIVE UPACC:
Q92871; A8K003; Q92586

BACKGROUND:
The enzyme Phosphomannomutase 1, with its alternative identifier PMMH-22, is crucial for the production of GDP-mannose and dolichol-phosphate-mannose, which are vital for mannosyl transfer reactions. This enzyme's function extends to potentially playing a role in mitigating the effects of ischemic damage in the brain by degrading glucose-1,6-bisphosphate, indicating its significance in both normal physiology and pathological conditions.

THERAPEUTIC SIGNIFICANCE:
The exploration of Phosphomannomutase 1's functions offers a promising pathway towards the development of therapeutic interventions. Given its essential role in mannosyl transfer reactions and potential involvement in brain ischemia recovery, targeting PMM1 could lead to innovative treatments for a range of metabolic and neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.